2EM Stock Overview
Ergomed plc, together with its subsidiaries, provides clinical trial planning, management, and monitoring; and drug safety and medical information services in the United Kingdom, rest of Europe, the Middle East, Africa, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Ergomed plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£11.00 |
| 52 Week High | UK£16.10 |
| 52 Week Low | UK£11.00 |
| Beta | 0.86 |
| 1 Month Change | 0% |
| 3 Month Change | -3.85% |
| 1 Year Change | -5.98% |
| 3 Year Change | 113.18% |
| 5 Year Change | 461.22% |
| Change since IPO | 349.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2EM | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 0% | 3.4% | 1.7% |
| 1Y | -6.0% | 0.5% | 9.4% |
Return vs Industry: 2EM exceeded the German Life Sciences industry which returned -23.6% over the past year.
Return vs Market: 2EM underperformed the German Market which returned 4.7% over the past year.
Price Volatility
| 2EM volatility | |
|---|---|
| 2EM Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 7.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2EM has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 2EM's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 1,400 | n/a | www.ergomedplc.com |
Ergomed plc, together with its subsidiaries, provides clinical trial planning, management, and monitoring; and drug safety and medical information services in the United Kingdom, rest of Europe, the Middle East, Africa, North America, and internationally. The company operates through two segments, Clinical Research Services and Pharmacovigilance. It provides and manages clinical development, trial management, and pharmacovigilance services for pharmaceutical, biotechnology, and generics companies.
Ergomed plc Fundamentals Summary
| 2EM fundamental statistics | |
|---|---|
| Market cap | €567.10m |
| Earnings (TTM) | €17.43m |
| Revenue (TTM) | €169.00m |
32.5x
P/E Ratio3.4x
P/S RatioIs 2EM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2EM income statement (TTM) | |
|---|---|
| Revenue | UK£145.26m |
| Cost of Revenue | UK£64.71m |
| Gross Profit | UK£80.55m |
| Other Expenses | UK£65.57m |
| Earnings | UK£14.98m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.30 |
| Gross Margin | 55.45% |
| Net Profit Margin | 10.31% |
| Debt/Equity Ratio | 0% |
How did 2EM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/06/28 17:44 |
| End of Day Share Price | 2023/03/31 00:00 |
| Earnings | 2022/12/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Ergomed plc is covered by 13 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Samuel England | Berenberg |
| Colin Grant | Davy |
| Jonas Peciulis | Edison Investment Research |